Trial Profile

Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
Focus Therapeutic Use
Acronyms Bullseye; Bullseye-2

Most Recent Events

30 Oct 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
30 Oct 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2025.
30 Oct 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com